TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01759823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation
Description: 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: 5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC's TRANSPLANTATION
Description: 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study: NCT02100306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback 100%
Description: Patients will receive constant auditory feedback across training trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback 50% alternate
Description: Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
Study: NCT04198675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised EMG Biofeedback Exercise Training Group
Description: Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise Training Group
Description: Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Posture Training/Ergonomic Regulations Group
Description: Posture training and ergonomic arrangements in the workplace.
Study: NCT02156336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 51 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, BID; for a maximum of 51 days.
Study: NCT03101085

Intervention type: DRUG
Group type: OTHER
Intervention: S-equol and Placebo
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and S-equol
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Study: NCT00067782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (immediate switch)
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (Week 24 switch)
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Study: NCT02757612

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: laser diode
Description: laser diode

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: laser diode
Description: laser diode
Study: NCT02014584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dutasteride matching placebo will be supplied as capsules to be administered orally.
Study: NCT03131882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: 1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
Study: NCT00880646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oolong tea containing L-arabinose and indigestible dextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oolong tea (Placebo)
Study: NCT01046214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl
Description: Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl
Description: Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
Study: NCT03845595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (LF-rTMS) group
Description: The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
Study: NCT01649024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT00955513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine gel 2.32%
Description: diclofenac diethylamine gel 2.32% twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine gel 2.32%
Description: diclofenac diethylamine gel 2.32% three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04716920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Attend Tai Chi exercise classes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Join Tai4Chijoint group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01653236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Study: NCT03462966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
Study: NCT01653236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Study: NCT04692142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped classroom teaching method
Description: Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flipped classroom teaching method
Description: Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
Study: NCT02239991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastometry
Description: Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
Study: NCT01868555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT01202058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVO™ Sirolimus-eluting Coronary Stent System
Description: Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study: NCT02859896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol (GZ427397)
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01868555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 30
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 45
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT01893736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-hospital professional support
Description: In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
Study: NCT01868555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT01893736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum telephone follow-up support
Description: Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
Study: NCT01862549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for children
Study: NCT01862549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT05210426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
Study: NCT01868555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT02664870

Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopic Surgery on the hip, shoulder, or knee

Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopic Surgery on the hip, shoulder, or knee

Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopic Surgery on the hip, shoulder, or knee

Intervention type: PROCEDURE
Intervention: Arthroplasty
Description: Total hip, shoulder, or knee arthroplasty
Study: NCT04383938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Pembrolizumab
Description: APR-246 D1-4 + Pembrolizumab D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Pembrolizumab
Description: APR-246 D1-4 + Pembrolizumab D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Pembrolizumab
Description: APR-246 D1-4 + Pembrolizumab D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Pembrolizumab
Description: APR-246 D1-4 + Pembrolizumab D3
Study: NCT03946085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumega-Z
Description: A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AREDS2
Description: A commercially-available multivitamin soft gel formula.
Study: NCT01702506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib fasted
Description: Overnight fasted subjects will receive a single 45 mg dose of dacomitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib fed
Description: Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib+antacid
Description: Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
Study: NCT02664870

Intervention type: PROCEDURE
Intervention: Arthroplasty
Description: Total hip, shoulder, or knee arthroplasty
Study: NCT03649009

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
Study: NCT01823991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VitaBlue™
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study: NCT03649009

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
Study: NCT01554995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg (Cohort 9) none
Study: NCT03424122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks followed by once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks followed by once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
Study: NCT01823991

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people.
Study: NCT02169609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab. Immunotherapy
Description: Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
Study: NCT02354417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: ProHema-CB
Description: Each subject will receive one administration of ProHema-CB unit transplant.
Study: NCT01823991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza®
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study: NCT01169402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 25mg/kg intravenously once weekly while on ECMO
Study: NCT03424122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
Study: NCT01653509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acyclovir patch
Description: Patch containing acyclovir

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Patch without acyclovir